Cypherpunk Technologies (NASDAQ:CYPH) Trading Down 6.1% - What's Next?

Key Points

• Shares fell 6.1% intraday to $0.8501 (low $0.8133) on ~1.9M shares traded—about 25% below average—with a market cap of ~$76.5M, a PE of 12.14, a 50‑day MA of $0.75 and a 200‑day MA of $0.95.
• Analyst sentiment remains weak: Weiss Ratings nudged the stock from "sell (d)" to "sell (d+)" but the consensus rating is still "Sell", even as several hedge funds added new Q4 positions (institutional ownership ~30.46%).
• Cypherpunk (formerly Leap Therapeutics) develops cancer therapies—its lead asset DKN‑01 is being tested alone and with pembrolizumab across multiple solid tumors—and the company also runs a digital‑asset treasury strategy centered on Zcash.

Shares of Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) were down 6.1% during trading on Wednesday . The stock traded as low as $0.8133 and last traded at $0.8501. Approximately 1,903,393 shares were traded during trading, a decline of 25% from the average daily volume of 2,548,861 shares. The stock had previously closed at $0.9050.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Cypherpunk Technologies from a "sell (d)" rating to a "sell (d+)" rating in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Sell".

Cypherpunk Technologies Trading Down 6.1%

The stock has a market capitalization of $76.49 million, a PE ratio of 12.14 and a beta of -0.22. The company's 50-day moving average is $0.75 and its 200 day moving average is $0.95.

Hedge Funds Weigh In On Cypherpunk Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Key Client Fiduciary Advisors LLC purchased a new position in shares of Cypherpunk Technologies in the 4th quarter valued at approximately $98,000. Sequoia Financial Advisors LLC purchased a new position in shares of Cypherpunk Technologies in the 4th quarter valued at approximately $56,000. Simplify Asset Management Inc. purchased a new position in shares of Cypherpunk Technologies in the 4th quarter valued at approximately $2,172,000. HighTower Advisors LLC purchased a new position in shares of Cypherpunk Technologies in the 4th quarter valued at approximately $59,000. Finally, Geode Capital Management LLC purchased a new position in shares of Cypherpunk Technologies in the 4th quarter valued at approximately $615,000. 30.46% of the stock is owned by hedge funds and other institutional investors.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.